In the global pharmaceutical manufacturing landscape, HK Neopharm Limited has been increasingly recognized by industry observers as a noteworthy participant in the active pharmaceutical ingredient ...
DUBLIN, May 10, 2021 /PRNewswire/ -- The "Global Active Pharmaceutical Ingredient Market (2020-2025) by Type, Molecule, Product Type, Formulation Type, Manufacturing Type, Synthesis Type, Drug Type, ...
Top API Manufacturer Expands Innovation and Global Supply Capabilities in Pharmaceutical Development
Zhejiang Hengkang Pharmaceutical Co., Ltd. continues to strengthen its position as a leading manufacturer within the global active pharmaceutical ingredient industry, attracting growing attention for ...
QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...
Teva Pharmaceuticals plans to remove 250 jobs at its CDMO unit over the next two years, Israeli business news outlet Globes ...
Eli Lilly’s breast cancer med Verzenio may look like your standard drug tablet—ovular, off-white, emblazoned with the dosage on the front and Lilly’s logo on the reverse—but behind that modest façade ...
The U.S. Veterinary API Manufacturing Market was valued at USD 2.02 Billion in 2025 and is projected to reach USD 4.84 Billion by 2035, while Europe is expected to grow from USD 2.02 Billion to USD 4.
India hosts more active pharmaceutical ingredient (API) manufacturing sites that are compliant with the U.S. Food and Drug Administration than any country outside the U.S., and it produces more ...
U.S. Market Projected to Reach USD 1.19 Billion by 2035, While Europe Advances Toward USD 0.94 Billion Amid Pharmaceutical Growth and REACH Compliance RequirementsAustin, June 20, 2026 (GLOBE NEWSWIRE ...
Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...
LONGMONT, Colo.--(BUSINESS WIRE)--Avista Pharma Solutions, Inc. (“Avista Pharma”) has completed facility upgrades that effectively double the company’s API manufacturing capacity at its Longmont, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results